Podcasts about vedolizumab

In this episode, Dr. Tarik Kani  interviews Dr Christian Agboton from USA about the optimal position of Vedolizumab in long-term Crohn's Disease

Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy by Gastroenterology Learning Network

ROMA (ITALPRESS) - Nuove speranze per la Pouchite, la complicanza che può insorgere nei pazienti con colite ulcerosa in seguito a proctocolectomia con confezionamento di pouch ileale. Se ne è parlato durante "Made for More", evento organizzato a Roma da Takeda, alla presenza di circa 300 clinici. A causa dei sintomi - tra cui diarrea, dolore e crampi addominali, ma anche febbre e disidratazione - la qualità di vita di chi soffre di questa patologia è significativamente compromessa. Ma un farmaco biologico, il vedolizumab, sta dimostrando la propria efficacia. f04/fsc/gsl

ROMA (ITALPRESS) - "La pouchite è un'infiammazione cronica della pouch dei pazienti con rettocolite cronica ulcerosa che sono andati incontro a colectomia e hanno ricostruito il loro retto. Il problema è che la necessità di più cicli di antibiotici porta a sintomi che impattano in maniera negativa sulla qualità della vita dei pazienti". Lo ha detto Silvio Danese, professore ordinario di Gastroenterologia presso l'Università Vita-Salute San Raffaele, a margine dell'evento Made for More, organizzato a Roma da Takeda, alla presenza e con la partecipazione di circa 300 clinici. "La novità dello studio EARNEST è l'efficacia di vedolizumab in pazienti che hanno pouchite cronica refrattaria e cioè ridare qualità di vita ai nostri pazienti inducendo remissione, migliorando la guarigione mucosale e anche l'infiammazione a livello istologico. Direi che sono ottime notizie, con il profilo di sicurezza di un farmaco che conosciamo da anni".f04/xi2/fsc/gsl

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Read the full article:Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS)

Katarzyna Pawlak talks to Dr Goessens (Belgium) about his recent paper on the efficacy and safety of combining biologic agents and small molecules in IBD, recognized with the UEG Journal 2022 Best Paper Award.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese.In questa puntata parliamo di:Sanofi, WelMed, Vaccino Covid-19, Vedolizumab, Distrofia Muscolare, Dermatite Atopica.Aziende: Sanofi, WelMed, EMA, Takeda.Persone: Alessandro Crevani (Sanofi), Alfonso Gentile (Takeda). Nuove terapie: Abrocitinib , meccanismo di auto-riparazione dei muscoli.Patologie: Dermatite atopica, Distrofia Muscolare.Lavoro: CRA 2 o Senior CRA.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/#Scienza, #clinica, #CRO, #Sanofi, #WelMed, #CRA, #Takeda, #Vedolizumab, #farmaceutico, #terapieinnovative, #DistrofiaMuscolare, #DermatiteAtopica, #Covid19, #Ricerca.

Puntata n° 140PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese.In questa puntata parliamo di:Sanofi, Alfasigma, ECDC-EMA, Covid-19, Morbo di Crohn.Aziende: Sanofi, Kadmon, Alfasigma, EMA, AIFA, Medtronic.Persone: Harlan Waksal (Kadmon).Nuove terapie: Vedolizumab, Vaccino.Patologie: Morbo di Crohn, Covid-19.Lavoro: Clinical Research Associate I, Senior Clinical Research Associate.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su:www.telegram.me/pharmapillswww.facebook.com/pharmapills/

NAMIJENJENO ISKLJUČIVO ZDRAVSTVENIM DJELATNICIMA. PRISTUPOM PODCASTU POTVRĐUJETE DA STE ZDRAVSTVENI DJELATNIK.PREDAVAČI:Prof.dr.sc. NERMIN SALKIĆspecijalista interne medicinesubspecijalista gastroenterohepatologvanredni profesor na Katedri za internu medicinuMedicinskog fakulteta Univerziteta u TuzliJZU UKC Tuzla, Klinika za interne bolestiPrim.dr. TATJANA BARAĆspecijalista interne medicinesubspecijalista gastroenterohepatologUKC RS BanjalukaKlinika za interne bolestiPrim.mr.sc. AIDA PILAVspecijalista interne medicinesubspecijalista gastroenterohepatologJZU UKC SarajevoKlinika za gastroenterohepatologijuDoc.dr.sc. MIRELA BAŠIĆ DENJAGIĆspecijalista interne medicineJZU UKC TuzlaKlinika za interne bolestiLINK NA TEČAJPristupom na CME aktivnost na Portalu CME.ba imate priliku da na kraju iste uradite završni test, te da dobijete akreditovani CME certifikat.Opet donosimo nešto posve novo. U saradnji sa farmaceutskom kućom Takeda i Video produkcijom KREATIVLUK, koja je i tehnički partner portala, predstavljamo Vam virtuelni simpozij, prvi u BiH. Vrhunska produkcija i zanimljiv klinički sadržaj su samo krune ove CME aktivnosti koja predstavlja užitak i za gledanje i za slušanje. Audio zapis ovog simpozija Vam danas donosimo u formi podcasta za Vašu lakšu i bržu edukaciju.U ovom virtuelnom simpoziju, po uzoru na najveće svjetske CME portale, donosimo diskusiju o tri vrlo zahtjevna slučaja pacijenata iz oblasti iz oblasti inflamatornih bolesti crijeva (IBD). Simpozij je dinamičan, protkan diskusijom o nekoliko vrlo zahtjevnih segmenata u tretmanu IBD, odnosno diskusijom o neuralgičnim tačkama koje često brinu sve one koji tretiraju ovakve pacijente.Toplo preporučujemo ovaj tečaj za Vašu pažnju i uživanje. Uvijek smo prvi kada je dostavljanje medicinskog znanja u pitanju.Tečaj je preporučen za sve zdravstvene djelatnike, a primjeren je i za studente medicine i magistre farmacije.----------Ukoliko želite postati partner portala CME.ba ili želite da se Vaš brand ili audio poruke pojave na našim podcastima, mollimo da se javite na email info@cme.ba. Više informacija za potencijalne partnere potražite na OVOM LINKU.TAKEDA Pharmaceuticals Better Health, Brighter Future.

FDA 批准新药用于治疗便秘型肠易激综合征Lancet 溃疡性结肠炎患者患结直肠癌的风险Nature Medicine 循环肿瘤DNA测序在晚期胃肠道肿瘤中的临床应用替那帕诺（tenapanor）替那帕诺（Tenapanor）是一种不被肠道吸收的、胃肠道钠/氢交换蛋白异构体3的小分子抑制剂。2019年9月，被FDA批准用于治疗成人便秘型肠易激综合征。《T3MPO-1研究：替那帕诺治疗便秘型肠易激综合征的3期临床研究》American Journal of Gastroenterology，2020年2月 (1)这项三期试验评估了替那帕诺 50 mg bid治疗便秘型肠易激综合征的有效性和安全性。研究纳入606例患者，随机分为替那帕诺组或安慰剂组，为期12周，然后进入4周的停药期。患者平均年龄45岁，81.4%女性。替那帕诺治疗组有27%的患者6周以上、每周腹痛减轻30%且至少一次自主排便；安慰剂组仅18.7%（P = 0.020）。替那帕诺对腹部症状和整体症状也有改善（P < 0.05）。腹泻是最常见的不良事件，在12周的治疗期间，分别有6.5%和0.7%的接受替那帕诺和安慰剂的患者停药。结论：替那帕诺50 mg bid可改善了便秘型肠易激综合征的症状，总体耐受性良好，为便秘型肠易激综合征患者提供了一个潜在的新的治疗选择。炎症性肠病炎症性肠病（inflammatory bowel disease，IBD）由两大类疾病组成，溃疡性结肠炎（ulcerative colitis，UC）和克罗恩病（Crohn's disease，CD）。溃疡性结肠炎特点是局限于结肠黏膜层的炎症复发与缓解交替出现，几乎均会累及直肠，并且通常向近端以连续性蔓延的方式累及结肠的其他部分。克罗恩病的特征是透壁性炎症和跳跃性病灶，导致管腔纤维化和狭窄，常见梗阻、窦道、穿孔。除了肠道症状外，可伴有口腔溃疡、关节炎、葡萄膜炎等。IBD的发病机制尚不清楚，主要危险因素包括：发病年龄有15-40岁和50-80岁两个高峰期；犹太人中更常见；家族史；吸烟；富含精加工、油炸、含糖食物西方膳食模式；感染和抗生素使用等。《3个前瞻性队列研究：饮食炎症的潜在和克罗恩病和溃疡性结肠炎的风险》Gastroenterology，2020年9月 (2)研究分析了来自3个大型的、前瞻性、队列性研究的数据，目的是评价饮食炎症能对克罗恩病和溃疡性结肠炎的患病风险的影响。研究收集了护士健康研究、护士健康研究II和卫生专业人员随访研究中的、166,903名女性和41,931名男性的数据。累计随访4,949,938人年，记录了328例克罗恩病和428例溃疡性结肠炎。诊断IBD的中位年龄为55岁。与累积平均、实证饮食炎症模式（Empirical dietary inflammatory pattern，EDIP）得分最低的四分位参与者相比，最高四分位的参与者患克罗恩病的风险高出51%（风险比1.51，P=0.01）。与实证饮食炎症模式评分持续较低的参与者相比，那些从低炎症潜能饮食、转变为促炎饮食，或持续摄入促炎饮食的参与者的、患克罗恩病的风险更大（风险比 2.05和 1.77）。相反，饮食中的炎症潜能与发生溃疡性结肠炎的风险无关。结论：在对3个大型前瞻性队列的分析中，我们发现高炎症潜能的饮食模式与克罗恩病风险增加有关，但与溃疡性结肠炎无关。《2项前瞻性队列研究：坚持地中海饮食可降低晚发克罗恩病的风险》Gut，2020年9月 (3)这2项前瞻性队列研究，共有83 147名参与者、年龄范围45-79岁，随访17年。随访中记录了克罗恩病164例，溃疡性结肠炎395例。改良地中海饮食依从性评分越高，克罗恩病风险越低（P=0.03），与溃疡性结肠炎无关。这种相关性不受年龄、性别、教育水平、体重指数或吸烟程度的影响。在研究中，地中海饮食依从性差的参与者患克罗恩率的比例为27%，这意味着患晚发性克罗恩病的人口归因风险为12%。结论：在2项前瞻性研究中，坚持地中海饮食可以显著降低晚发克罗恩病的风险。《前瞻性病例对照研究：抗生素的使用和IBD的发展》Lancet Gastroenterology & Hepatology，2020年11月 (4)早期使用抗生素与儿童IBD有关，但成年人IBD的关系尚不确定调查抗生素治疗和IBD之间的关系，在一个大规模的，以人群为基础的研究。在这项前瞻性病例对照研究中，纳入了新确诊了23 982例IBD患者（15 951例溃疡性结肠炎，7898例克罗恩病，133例未分类IBD），117 827例对照组和28 732同胞兄妹。在调整了几种危险因素后，使用抗生素的患者IBD发病的风险比为1·88，溃疡性肠炎的风险比1·74，克罗恩病的风险比2·27，均有统计学意义。接受1次抗生素、2次抗生素、≥3次抗生素的IBD风险比分别为1.11、1.38和1·55，显著高于没有使用抗生素的患者。使用≥3种抗生素的人群中，溃疡性结肠炎发病风险比1·47，克罗恩病发病风险比1·64，均显著增加。当同胞兄妹作为参照组时，观察到类似的结果，但相关性减弱，≥3种抗生素时风险比1·35。结论：抗生素治疗累积暴露，可能与新发IBD风险增加相关。《基础研究：使用生物标志物识别5年内将发展为克罗恩病的患者》Gastroenterology，2020年7月 (5)研究的目的是鉴定克罗恩病和溃疡性结肠炎的，诊断前即可检测、量化的血清生物标记物。研究人员提取了200例克罗恩病，199例溃疡性结肠炎以及200名健康个体的血清样本，测量了针对微生物的抗体（抗酿酒酵母IgA或IgG、抗大肠杆菌外膜孔蛋白C、抗CBir1、抗鞭毛蛋白2、抗鞭毛蛋白X和核周抗中性粒细胞细胞质抗体）以及1129个蛋白的水平。然后使用功能主成分分析来推导每个标记的时变轨迹，将其用于多变量模型来预测疾病状态，克罗恩病患者血清中上调的生物学途径是根据诊断前不同时期蛋白丰度的变化确定的。研究人员鉴定了一组51个蛋白生物标记物，预测5年内诊断克罗恩病的曲线下面积为0.76，预测1年内诊断克罗恩病的曲线下面积为0.87。结论：我们鉴定了一组血清抗体和蛋白，它们可以预测患者在5年内获得高准确度的克罗恩病诊断。相比之下，我们没有确定与溃疡性结肠炎的未来诊断相关的生物标记物。《基于人群的队列研究：溃疡性结肠炎中的结直肠癌》Lancet，2020年1月(6)研究的目的是比较溃疡性结肠炎患者结直肠癌的发生率和死亡率的风险。这个以人群为基础的队列研究中，纳入48年间、96 447例溃疡性结肠炎患者。溃疡性结肠炎中发生结直肠癌的几率是1·29/1000人年，风险比 1·66。溃疡性结肠炎中死于结直肠癌的几率是0·55/1000人年，风险比 1·59。虽然溃疡性结肠炎患者发现结直肠癌时的分期较早（p

FRI0294 - Vedolizumab in IBD with Spondyloarthritis

Dr. Asit Parikh, MD, SVP, and head of the Gastrointestinal Therapeutic Area at Takeda Pharmaceutical Company Limited discusses new data presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab (Entyvio®) for use during maintenance therapy in adult patients with moderately to severely active Crohn's disease (CD).

Prevalence and Incidence of Intestinal Metaplasia and Dysplasia of Gastric Cardia in Barrett's Esophagus After Endoscopic Therapy. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:ClinOpsHub, Assunzioni nel farmaceutico, Artrite reumatoide, Malattia di Crohn, Aflibercept.Aziende: ClinOpsHub Srl, Clinipace, AstraZeneca.Persone: Stefano Lagravinese, Giorgia Latteri, Luca Giordano, Valeria Scoditti (ClinOpsHub Srl), Massimo Scaccabarozzi (Farmindustria), Luigi Sinigaglia (Società Italiana di Reumatologia), Silvio Danese (Centro Malattie Infiammatorie Croniche Intestinali - Humanitas), Andreas Stahl (Clinica Oculistica Universitaria di Greifswald).Nuove terapie: Vedolizumab, aflibercept. Patologie: Malattia di Crohn, Retinopatia del prematuro (ROP).Lavoro: Senior CRA (Milano), Medical Evidence and Observational Research, Senior CRA (Roma).Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapills www.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:ClinOpsHub, Assunzioni nel farmaceutico, Artrite reumatoide, Malattia di Crohn, Aflibercept.Aziende: ClinOpsHub Srl, Clinipace, AstraZeneca.Persone: Stefano Lagravinese, Giorgia Latteri, Luca Giordano, Valeria Scoditti (ClinOpsHub Srl), Massimo Scaccabarozzi (Farmindustria), Luigi Sinigaglia (Società Italiana di Reumatologia), Silvio Danese (Centro Malattie Infiammatorie Croniche Intestinali - Humanitas), Andreas Stahl (Clinica Oculistica Universitaria di Greifswald).Nuove terapie: Vedolizumab, aflibercept. Patologie: Malattia di Crohn, Retinopatia del prematuro (ROP).Lavoro: Senior CRA (Milano), Medical Evidence and Observational Research, Senior CRA (Roma).Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapills www.facebook.com/pharmapills/

New data shed little light on if screening individuals at high-risk for pancreatic cancer is effective and cost-effective in the long term. Tofacitinib-induction therapy reduces symptoms within 3 days for patients with UC. Vedolizumab is effective for adult UC patients who are anti-tumor necrosis factor naive. ESD is safer and more effective than esophagectomy for early-stage esophageal squamous cell carcinoma. New findings show that endoscopic ultrasound accurately distinguishes celiac lymph nodes and celiac ganglia.

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population). METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received. RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% ...

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population). METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received. RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% ...

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population). METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received. RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% ...

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population). METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received. RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% ...

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Sands BE1, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis factor-alpha (TNF-α) antagonist therapy (TNF-naïve) or who had discontinued TNF-α antagonist therapy because of inadequate response (i.e., primary nonresponse), loss of response, or intolerance (collectively classified as the TNF-failure population). METHODS: Post hoc analyses of the efficacy data for 516 TNF-naïve and 960 TNF-failure patients from the GEMINI 2 and GEMINI 3 trials were evaluated at weeks 6, 10, and 52 and included clinical remission (CD Activity Index [CDAI] score ≤150), enhanced clinical response (≥100-point decrease from baseline in CDAI score), durable clinical remission (remission at ≥80% of visits), and corticosteroid-free remission. Adverse events were summarized for the TNF-naïve and TNF-failure subgroups by treatment received. RESULTS: Among patients who responded to vedolizumab induction at week 6, 48.9% ...

A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn's disease for whom tumor necrosis factor (TNF) antagonists have already failed. Dr. Kuemmerle speaks with Dr. Bruce E. Sands

Today in FirstWord:

Today in FirstWord: